Hyoscyamine

Generic name: Pronounced as (hye oh sye' a meen)
Brand names
  • Cystospaz®
  • ED-Spaz®
  • Hyomax®
  • Hyophen®
  • Hyosyne®
  • Levsin®
  • Oscimin®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 09/15/2017

Hyoscyamine is used to control symptoms associated with disorders of the gastrointestinal (GI) tract. It works by decreasing the motion of the stomach and intestines and the secretion of stomach fluids, including acid. Hyoscyamine is also used in the treatment of bladder spasms, peptic ulcer disease, diverticulitis, colic, irritable bowel syndrome, cystitis, and pancreatitis. Hyoscyamine may also be used to treat certain heart conditions, to control the symptoms of Parkinson's disease and rhinitis (runny nose), and to reduce excess saliva production.

Hyoscyamine comes as a tablet, an extended-release (long-acting) capsule, and a liquid to take by mouth. The tablets and liquid are usually taken three or four times a day. The extended-release capsules are usually taken twice a day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take hyoscyamine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the extended-release tablets whole; do not split, chew, or crush them.

Hyoscyamine controls symptoms associated with disorders of the GI tract, but it does not cure the disorders. Continue to take hyoscyamine even if you feel well. Do not stop taking hyoscyamine without talking to your doctor.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

Before taking hyoscyamine,

  • tell your doctor and pharmacist if you are allergic to hyoscyamine, any other medications, or any of the ingredients in hyoscyamine tablets, capsules, or liquid. Ask your doctor or pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking pr plan to take. Be sure to mention any of the following: amantadine (Symadine, Symmetrel), amitriptyline (Elavil), chlorpromazine (Thorazine), clomipramine (Anafranil), desipramine (Norpramin), doxepin (Sinequan), fluphenazine (Prolixin), haloperidol (Haldol), imipramine (Tofranil), medications containing belladonna (Donnatal), mesoridazine (Serentil), nortriptyline (Pamelor), perphenazine (Trilafon), phenelzine (Nardil), prochlorperazine (Compazine), promazine (Sparine), promethazine (Phenergan), protriptyline (Vivactil), thioridazine (Mellaril), tranylcypromine (Parnate), trifluoperazine (Stelazine), triflupromazine (Vesprin), trimeprazine (Temaril), and trimipramine (Surmontil). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • be aware that antacids may interfere with hyoscyamine, making it less effective. Take hyoscyamine 1 hour before or 2 hours after antacids.

  • tell your doctor if you have or have ever had glaucoma; heart, lung, liver, or kidney disease; a urinary tract or intestinal obstruction; an enlarged prostate; ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum); or myasthenia gravis.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking hyoscyamine, call your doctor.

  • talk to your doctor about the risks and benefits of taking hyoscyamine if you are 65 years of age or older. Older adults should not usually take hyoscyamine because it is not as safe and may not be as effective as other medications that can be used to treat the same condition.

  • if you are having surgery, including dental surgery, tell your doctor or dentist that you take hyoscyamine.

  • you should know that this medication may make you drowsy. Do not drive a car or operate machinery until you know how hyoscyamine affects you.

  • ask your doctor about the safe use of alcohol during your treatment with hyoscyamine. Alcohol can make the side effects of this medication worse.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Hyoscyamine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • drowsiness

    • dizziness or lightheadedness

    • headache

    • blurred vision

    • flushing (feeling of warmth)

    • dry mouth

    • constipation

    • difficulty urinating

    • increased sensitivity to light

  • Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:

    • diarrhea

    • skin rash

    • eye pain

    • fast or irregular heartbeat

  • Hyoscyamine may cause other side effects. Call your doctor if you have any unusual problems while you are taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Keep all appointments with your doctor and the laboratory.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Moxifloxacin.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Dolasetron.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Anagrelide.
Bisacodyl Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Hyoscyamine.
Calcium Carbonate Calcium Carbonate Calcium carbonate can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Cilostazol.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hyoscyamine.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Erythromycin.
Guanfacine Guanfacine Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Magnesium Hydroxide Magnesium Hydroxide Magnesium hydroxide can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Oxide Magnesium Oxide Magnesium oxide can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Naratriptan Naratriptan Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Paregoric Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Hyoscyamine.
Penbutolol Penbutolol Hyoscyamine may increase the arrhythmogenic activities of Acebutolol.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Hyoscyamine.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hyoscyamine.
Psyllium Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Hyoscyamine.
Reserpine Reserpine Reserpine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Rizatriptan Rizatriptan Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Sumatriptan Sumatriptan Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Tacrolimus Tacrolimus The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Tacrolimus.
Tizanidine Tizanidine Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Zolmitriptan Zolmitriptan Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Famotidine.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Hyoscyamine.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Foscarnet.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Hyoscyamine.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Levofloxacin.
Meperidine Injection Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Hyoscyamine.
Metoclopramide Injection Metoclopramide Injection The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Metoclopramide.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Metronidazole.
Morphine Injection Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Hyoscyamine.
Altretamine Altretamine Amphetamine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ondansetron.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Granisetron.
Olanzapine Olanzapine Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Alosetron Alosetron Alosetron may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Dofetilide Dofetilide Hyoscyamine may increase the arrhythmogenic activities of Dofetilide.
Entacapone Entacapone Entacapone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Hydroxychloroquine Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Hydroxychloroquine.
Oxcarbazepine Oxcarbazepine Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Zaleplon Zaleplon Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Desloratadine Desloratadine Hyoscyamine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
Linezolid Linezolid Linezolid may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Rivastigmine Rivastigmine The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Rivastigmine.
Trimipramine Trimipramine Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Glycopyrrolate Glycopyrrolate The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Glycopyrronium.
Epinephrine Injection Epinephrine Injection The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Epinephrine.
Escitalopram Escitalopram The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Escitalopram.
Zonisamide Zonisamide Zonisamide may increase the arrhythmogenic activities of Hyoscyamine.
Aripiprazole Aripiprazole Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Atomoxetine Atomoxetine Atomoxetine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Dexmethylphenidate Dexmethylphenidate Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Atazanavir.
Almotriptan Almotriptan Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Eletriptan Eletriptan Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Hyoscyamine.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hyoscyamine.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Vardenafil.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Hyoscyamine.
Memantine Memantine The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Memantine.
Tegaserod Tegaserod The therapeutic efficacy of Tegaserod can be decreased when used in combination with Hyoscyamine.
Frovatriptan Frovatriptan Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Gemifloxacin.
Apomorphine Injection Apomorphine Injection Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Protriptyline Protriptyline Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Duloxetine Duloxetine Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Trospium Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Hyoscyamine.
Erlotinib Erlotinib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Erlotinib.
Eszopiclone Eszopiclone Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Solifenacin.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Voriconazole.
Dextroamphetamine Dextroamphetamine Amphetamine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Pramlintide Injection Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Hyoscyamine.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ibandronate.
Isocarboxazid Isocarboxazid Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Ramelteon Ramelteon Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Darifenacin Darifenacin The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Darifenacin.
Fentanyl Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Hyoscyamine.
Pregabalin Pregabalin Pregabalin may increase the arrhythmogenic activities of Hyoscyamine.
Phenylephrine Phenylephrine The risk or severity of Tachycardia can be increased when Phenylephrine is combined with Hyoscyamine.
Felbamate Felbamate Felbamate may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Ranolazine Ranolazine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ranolazine.
Rasagiline Rasagiline Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Imatinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Salbutamol.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Paliperidone.
Bortezomib Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Hyoscyamine.
Lubiprostone Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Hyoscyamine.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Oxaliplatin.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Posaconazole.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Primaquine.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Dimenhydrinate.
Lisdexamfetamine Lisdexamfetamine The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Lisdexamfetamine.
Nabilone Nabilone The risk or severity of Tachycardia and drowsiness can be increased when Hyoscyamine is combined with Nabilone.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Vorinostat.
Sorafenib Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Hyoscyamine.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Sunitinib.
Dronabinol Dronabinol The risk or severity of Tachycardia and drowsiness can be increased when Hyoscyamine is combined with Dronabinol.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Lapatinib.
Levocetirizine Levocetirizine Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Dasatinib.
Mexiletine Mexiletine Mexiletine may increase the arrhythmogenic activities of Hyoscyamine.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Hyoscyamine.
Nilotinib Nilotinib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Toremifene.
Betaine Betaine The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Glycine betaine.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Botulinum toxin type A.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Botulinum Toxin Type B.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Nebivolol Nebivolol Hyoscyamine may increase the arrhythmogenic activities of Nebivolol.
Flecainide Flecainide Hyoscyamine may increase the arrhythmogenic activities of Flecainide.
Rufinamide Rufinamide Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Midazolam Midazolam Midazolam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Naltrexone Injection Naltrexone Injection The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Naltrexone.
Milnacipran Milnacipran Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Sodium Phosphate Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Hyoscyamine.
Fesoterodine Fesoterodine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Degarelix.
Betaxolol Betaxolol Hyoscyamine may increase the arrhythmogenic activities of Betaxolol.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Iloperidone.
Lacosamide Lacosamide Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Dronedarone Dronedarone Hyoscyamine may increase the arrhythmogenic activities of Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Botulinum toxin type A.
Palonosetron Injection Palonosetron Injection Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Romidepsin.
Tapentadol Tapentadol The risk or severity of adverse effects can be increased when Tapentadol is combined with Hyoscyamine.
Pazopanib Pazopanib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Pazopanib.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Asenapine.
Vigabatrin Vigabatrin Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Hyoscyamine.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Eribulin.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Botulinum toxin type A.
Lurasidone Lurasidone Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Vilazodone Vilazodone Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Hyoscyamine.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Rilpivirine.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Triptorelin.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Vandetanib.
Clobazam Clobazam Clobazam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Vemurafenib.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Crizotinib.
Cabergoline Cabergoline Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Ezogabine Ezogabine Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Mirabegron Mirabegron The risk or severity of urinary retention can be increased when Hyoscyamine is combined with Mirabegron.
Linaclotide Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Hyoscyamine.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Bedaquiline.
Pomalidomide Pomalidomide Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Dabrafenib.
Levomilnacipran Levomilnacipran Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Vortioxetine Vortioxetine Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Droxidopa Droxidopa The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Droxidopa.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ceritinib.
Eslicarbazepine Eslicarbazepine Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Hydrocodone Hydrocodone The risk or severity of adverse effects can be increased when Hydrocodone is combined with Hyoscyamine.
Suvorexant Suvorexant Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Methamphetamine Methamphetamine Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Tasimelteon Tasimelteon Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Risperidone Injection Risperidone Injection Risperidone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Lenvatinib.
Panobinostat Panobinostat The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Haloperidol.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ivabradine.
Flibanserin Flibanserin Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Brexpiprazole Brexpiprazole Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ziprasidone.
Cariprazine Cariprazine Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Eluxadoline Eluxadoline The risk or severity of constipation can be increased when Hyoscyamine is combined with Eluxadoline.
Brivaracetam Injection Brivaracetam Injection Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Midodrine Midodrine The risk or severity of Tachycardia can be increased when Midodrine is combined with Hyoscyamine.
Pimavanserin Pimavanserin Pimavanserin may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Diphenhydramine Injection Diphenhydramine Injection Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) Doxepin may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Plecanatide Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Hyoscyamine.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Deutetrabenazine.
Safinamide Safinamide Safinamide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Delafloxacin.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Tetrabenazine.
Buprenorphine Injection Buprenorphine Injection The risk or severity of adverse effects can be increased when Buprenorphine is combined with Hyoscyamine.
Lofexidine Lofexidine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Lofexidine.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Encorafenib.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ivosidenib.
Cannabidiol Cannabidiol The risk or severity of Tachycardia and drowsiness can be increased when Hyoscyamine is combined with Cannabidiol.
Stiripentol Stiripentol Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Glasdegib.
Prucalopride Prucalopride The therapeutic efficacy of Prucalopride can be decreased when used in combination with Hyoscyamine.
Magnesium Citrate Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Hyoscyamine.
Brexanolone Injection Brexanolone Injection Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Solriamfetol Solriamfetol The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Hyoscyamine.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Entrectinib.
Pitolisant Pitolisant Hyoscyamine may increase the QTc-prolonging activities of Pitolisant.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Hyoscyamine.
Phenytoin Injection Phenytoin Injection Phenytoin may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Fosphenytoin Injection Fosphenytoin Injection Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Lumateperone Lumateperone Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Lasmiditan Lasmiditan Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Lemborexant Lemborexant Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Fenfluramine Fenfluramine Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Fostemsavir.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hyoscyamine.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Relugolix.
Viloxazine Viloxazine Viloxazine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Hyoscyamine.
Sodium Bicarbonate Sodium Bicarbonate Sodium bicarbonate can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Metaxalone Metaxalone Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Hyoscyamine.
Primidone Primidone Primidone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Methsuximide Methsuximide Methsuximide may increase the arrhythmogenic activities of Hyoscyamine.
Diethylpropion Diethylpropion Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Chlorpromazine Chlorpromazine Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Diazepam Diazepam Diazepam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Oxazepam Oxazepam Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Flurazepam Flurazepam Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Clorazepate Clorazepate Clorazepic acid may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Lorazepam Lorazepam Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Amantadine.
Codeine Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Hyoscyamine.
Meprobamate Meprobamate Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Chlordiazepoxide Chlordiazepoxide Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Bromocriptine Bromocriptine Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Metaproterenol Metaproterenol The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Orciprenaline.
Tranylcypromine Tranylcypromine Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Phenelzine Phenelzine Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Procarbazine Procarbazine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Ergoloid Mesylates Ergoloid Mesylates Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Prochlorperazine Prochlorperazine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Prochlorperazine.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Thioridazine.
Trifluoperazine Trifluoperazine Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Hyoscyamine.
Methadone Methadone The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Methadone.
Oxybutynin Oxybutynin The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxybutynin.
Benztropine Benztropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Hyoscyamine.
Maprotiline Maprotiline Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Trihexyphenidyl Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hyoscyamine.
Orphenadrine Orphenadrine Orphenadrine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Perphenazine Perphenazine Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Fluphenazine Fluphenazine Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Phentermine Phentermine The risk or severity of Tachycardia can be increased when Phentermine is combined with Hyoscyamine.
Amoxapine Amoxapine Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Mechlorethamine Mechlorethamine The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Mechlorethamine.
Pyridostigmine Pyridostigmine The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Pyridostigmine.
Carbamazepine Carbamazepine Carbamazepine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Molindone Molindone Molindone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Clonidine Clonidine Clonidine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Clonazepam Clonazepam Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Loperamide Loperamide Hyoscyamine may increase the arrhythmogenic activities of Loperamide.
Promethazine Promethazine Promethazine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Digoxin Digoxin Digoxin may increase the arrhythmogenic activities of Hyoscyamine.
Loxapine Loxapine Loxapine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Chloroquine.
Quinine Quinine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Quinine.
Ethosuximide Ethosuximide Ethosuximide may increase the arrhythmogenic activities of Hyoscyamine.
Lactulose Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Hyoscyamine.
Chlorothiazide Chlorothiazide The serum concentration of Chlorothiazide can be increased when it is combined with Hyoscyamine.
Chlorthalidone Chlorthalidone The serum concentration of Chlorthalidone can be increased when it is combined with Hyoscyamine.
Metolazone Metolazone The serum concentration of Metolazone can be increased when it is combined with Hyoscyamine.
Secobarbital Secobarbital Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Desipramine Desipramine Desipramine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Amitriptyline Amitriptyline The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Amitriptyline.
Imipramine Imipramine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Imipramine.
Quinidine Quinidine Hyoscyamine may increase the arrhythmogenic activities of Quinidine.
Procainamide Procainamide Hyoscyamine may increase the arrhythmogenic activities of Procainamide.
Disopyramide Disopyramide Hyoscyamine may increase the arrhythmogenic activities of Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Valproic acid.
Tamoxifen Tamoxifen The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Tamoxifen.
Butabarbital Butabarbital Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Glucagon Injection Glucagon Injection Hyoscyamine may increase the gastrointestinal motility reducing activities of Glucagon.
Dextromethorphan Dextromethorphan Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Cyclobenzaprine Cyclobenzaprine Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Baclofen Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Cyproheptadine Cyproheptadine Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Chlorpheniramine.
Brompheniramine Brompheniramine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Meclizine Meclizine Meclizine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Methyclothiazide Methyclothiazide The serum concentration of Methyclothiazide can be increased when it is combined with Hyoscyamine.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Hydrochlorothiazide.
Dantrolene Dantrolene Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Chlorzoxazone Chlorzoxazone Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Carisoprodol Carisoprodol Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Methocarbamol Methocarbamol Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Disulfiram.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) Hyoscyamine may increase the arrhythmogenic activities of Propranolol.
Pseudoephedrine Pseudoephedrine The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Pseudoephedrine.
Nortriptyline Nortriptyline Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Nadolol Nadolol Hyoscyamine may increase the arrhythmogenic activities of Nadolol.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Hyoscyamine.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Hyoscyamine.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hyoscyamine.
Trimethobenzamide Trimethobenzamide Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Flavoxate Flavoxate The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Fluorouracil.
Acetazolamide Acetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Ketoconazole Ketoconazole The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ketoconazole.
Pyrantel Pyrantel Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Thiotepa Injection Thiotepa Injection The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Thiotepa.
Isoxsuprine Isoxsuprine The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Isoxsuprine.
Metoprolol Metoprolol Metoprolol may increase the arrhythmogenic activities of Hyoscyamine.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Hyoscyamine.
Thiothixene Thiothixene Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Alprazolam Alprazolam Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Temazepam Temazepam Temazepam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Triazolam Triazolam Triazolam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Dicyclomine Dicyclomine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dicyclomine.
Propantheline Propantheline The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Propantheline.
Diltiazem Diltiazem Hyoscyamine may increase the arrhythmogenic activities of Diltiazem.
Nifedipine Nifedipine Hyoscyamine may increase the arrhythmogenic activities of Nifedipine.
Timolol Timolol Timolol may increase the arrhythmogenic activities of Hyoscyamine.
Verapamil Verapamil Hyoscyamine may increase the arrhythmogenic activities of Verapamil.
Atenolol Atenolol Atenolol may increase the arrhythmogenic activities of Hyoscyamine.
Pindolol Pindolol Pindolol may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Cisplatin Injection Cisplatin Injection The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Cisplatin.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Indapamide.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Pentamidine.
Labetalol Labetalol The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Labetalol.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Leuprolide.
Guanabenz Guanabenz The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Guanabenz.
Pimozide Pimozide The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Pimozide.
Amiodarone Amiodarone The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Amiodarone.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ciprofloxacin.
Fluoxetine Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Hyoscyamine.
Nimodipine Nimodipine Hyoscyamine may increase the arrhythmogenic activities of Nimodipine.
Clozapine Clozapine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Clozapine.
Estazolam Estazolam Estazolam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ofloxacin.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Clarithromycin.
Felodipine Felodipine Hyoscyamine may increase the arrhythmogenic activities of Felodipine.
Amlodipine Amlodipine Amlodipine may increase the arrhythmogenic activities of Hyoscyamine.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Itraconazole.
Sotalol Sotalol Hyoscyamine may increase the arrhythmogenic activities of Sotalol.
Bisoprolol Bisoprolol The therapeutic efficacy of Hyoscyamine can be increased when used in combination with Bisoprolol.
Zolpidem Zolpidem Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Isradipine Isradipine Isradipine may increase the arrhythmogenic activities of Hyoscyamine.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Cisapride.
Gabapentin Gabapentin Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Venlafaxine Venlafaxine Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Nizatidine Nizatidine The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Nizatidine.
Fluvoxamine Fluvoxamine Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Nefazodone Nefazodone Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Lamotrigine Lamotrigine Lamotrigine may increase the arrhythmogenic activities of Hyoscyamine.
Losartan Losartan Hyoscyamine may increase the arrhythmogenic activities of Losartan.
Tramadol Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Hyoscyamine.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Moexipril.
Nicardipine Nicardipine Hyoscyamine may increase the arrhythmogenic activities of Nicardipine.
Bupropion Bupropion Bupropion may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Saquinavir.
Nisoldipine Nisoldipine Nisoldipine may increase the arrhythmogenic activities of Hyoscyamine.
Riluzole Riluzole Riluzole may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Glimepiride Glimepiride Glimepiride may increase the arrhythmogenic activities of Hyoscyamine.
Ritonavir Ritonavir The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ritonavir.
Clomipramine Clomipramine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Clomipramine.
Mirtazapine Mirtazapine Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Topiramate Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Hyoscyamine is combined with Topiramate.
Donepezil Donepezil The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Donepezil.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Hyoscyamine.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Azithromycin.
Loratadine Loratadine Hyoscyamine may increase the anticholinergic activities of Loratadine.
Carvedilol Carvedilol Hyoscyamine may increase the arrhythmogenic activities of Carvedilol.
Selegiline Selegiline Selegiline may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Sertraline Sertraline Sertraline may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Propafenone Propafenone Hyoscyamine may increase the arrhythmogenic activities of Propafenone.
Ropinirole Ropinirole Ropinirole may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Quetiapine Quetiapine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Quetiapine.
Cetirizine Cetirizine Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Paroxetine Paroxetine Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Tolcapone Tolcapone Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Citalopram.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Efavirenz.
Tolterodine Tolterodine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Tolterodine.
Thalidomide Thalidomide Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Aluminum Hydroxide Aluminum Hydroxide Aluminum hydroxide can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Hyoscyamine.
Levetiracetam Levetiracetam Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists